Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05563272
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Overview
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Sponsor
Telix PharmaceuticalsPhase
Phase 2
Contacts
Kavita Vadali
global-clinicaltrials@telixpharma.com
+61 3 9093 3808
ClinicalTrials.gov
NCT05563272Drug / Compound
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
Eligibility
Inclusion
- Histologically or cytologically proven solid tumors
- Male or female >= 18 years old
- At least one non-CNS, measurable target lesion per RECIST 1.1 documented at conventional imaging within 30 days prior
Exclusion
- Previous administration of any radionuclide within 10 half-lives prior to administration of 89Zr-girentuximab
- Exposure to any antineoplastic treatment within 14 days from planned administration
- Exposure to any CAIX-targeting compound in the last 3 months
Patient Education
Patient education not yet provided.
Publications
Locations
Loading…
Share your feedback
Help us improve your experience